1. Walzer PD, Smulian AG. Pneumocystis species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th edition. Philadelphia: Elsevier Churchill Livings-
tone; 2010.
2. Gigliotti F, Limper AH, Wright T. Pneumocystis. Cold Spring Harb Perspect Med 2014; 4: a019828.
3. Matos O, Tomas AL, Antunes F. Pneumocystis jirovecii and Pneumocystosis. In: Mora-Montes HM, Lopes-Bezerra LM, eds. Current Progress in Medical Mycology. Cham, Switzerland: Sprin-
ger; 2017.
4. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-2498.
5. Ma, L. Pneumocystis: An Atypical Fungal Pathogen. In: Reference Module in Biomedical Sciences. Elsevier; 2015.
6. Eades CP, Miller RF. Pneumocystis. In: Janes SM, ed. Encyclopedia of Respiratory Medicine. 2nd edition. Academic Press; 2021.
7. Truong J, Ashurst JV. Pneumocystis jirovecii Pneumonia. [Updated 2023 Jan 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.
ncbi.nlm.nih.gov/books/NBK482370/
8. Schoch CL, Ciufo S, Domrachev M, et al. NCBI Taxonomy: a comprehensive update on curation, resources and tools. Database (Oxford) 2020; 2020: baaa062.
9. Xue T, Kong X, Ma L. Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection. J Fungi 2023; 9: 812.
10. Cushion MT, Tisdale-Macioce N, Sayson SG, Porollo A. The Persistent Challenge of Pneumocystis Growth Outside the Mammalian Lung: Past and Future Approaches. Front Microbiol 2021;
12: 681474.
11. Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol 1999; 46: 89S-92S.
12. Stringer JR, Beard CB, Miller RF. Spelling Pneumocystis jirovecii. Emerg Infect Dis 2009; 15: 506.
13. Gigliotti F, Wright TW. Pneumocystis jirovecii. In: Long SS, Prober CG, Fischer M, Kimberlin DW, eds. Principles and Practice of Pediatric Infectious Diseases. 6th edition. Elsevier; 2022.
14. Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol 2010; 5: 43-65.
15. Ma L, Chen Z, Huang DW, et al. Diversity and Complexity of the Large Surface Protein Family in the Compacted Genomes of Multiple Pneumocystis Species. mBio 2020; 11: e02878-19.
16. Daly KR, Koch J, Levin L, Walzer PD. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg Infect Dis 2004; 10: 848-854.
17. Stringer JR. Antigenic Variation in Pneumocystis. J Eukaryot Microbiol 2007; 54: 8-13.
18. Kutty G, Davis AS, Ferreyra GA, et al. β-Glucans Are Masked but Contribute to Pulmonary Inflammation During Pneumocystis Pneumonia. J Infect Dis 2016; 214: 782-91.
19. Chabe M, Aliouat-Denis CM, Delhaes L, Aliouat el M, Viscogliosi E, Dei-Cas E. Pneumocystis: from a doubtful unique entity to a group of highly diversified fungal species. FEMS Yeast Res
2011; 11: 2-17.
20. Kaneshiro ES. Sterol metabolism in the opportunistic pathogen Pneumocystis: advances and new insights. Lipids 2004; 39: 753-761.
21. Agarwal R, Reddy C, Aggarwal AN, Saxena AK. It’s Pneumocystis jiroveci not Pneumocystis carinii. Chest 2006; 129: 498.
22. Apostolopoulou A, Fishman JA. The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia. J Fungi 2022; 8: 1167.
23. Damiani C, Choukri F, Le Gal S, et al. Possible nosocomial transmission of Pneumocystis jirovecii. Emerg Infect Dis 2012; 18: 877-878.
24. Medrano FJ, Montes-Cano M, Conde M, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005; 11: 245-250.
25. Nevez G, Magois E, Duwat H, Gouilleux V, Jounieaux V, Totet A. Apparent absence of Pneumocystis jirovecii in healthy subjects. Clin Infect Dis 2006; 42: 99-101.
26. Huang L, Morris A, Limper AH, Beck JM; ATS Pneumocystis Workshop Participants. An Official ATS Workshop Summary: Recent advances and future directions in Pneumocystis pneumonia
(PCP). Proc Am Thorac Soc 2006; 3: 655-664.
27. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10: 1713-1720.
28. Dellière S, Gits-Muselli M, Bretagne S, Alanio A. Outbreak-Causing Fungi: Pneumocystis jirovecii. Mycopathologia 2020; 185: 783-800.
29. Epling BP, Manion M, Sirajuddin A, et al. Long-term Outcomes of Patients With HIV and Pneumocystis jirovecii Pneumonia in the Antiretroviral Therapy Era. Open Forum Infect Dis 2023;
10: ofad408.
30. Chesnay A, Paget C, Heuzé-Vourc’h N, Baranek T, Desoubeaux G. Pneumocystis Pneumonia: Pitfalls and Hindrances to Establishing a Reliable Animal Model. J Fungi 2022; 8: 129.
31. Veintimilla C, Álvarez-Uría A, Martín-Rabadán P, et al. Pneumocystis jirovecii Pneumonia Diagnostic Approach: Real-Life Experience in a Tertiary Centre. J Fungi 2023; 9: 414.
32. Diaz-Abad M, Robinett KS, Lasso-Pirot A, Legesse TB, Khambaty M. Granulomatous Pneumocystis jiroveci Pneumonia in an HIV-Positive Patient on Antiretroviral Therapy: A Diagnostic
Challenge. Open Respir Med J 2021; 15: 19-22.
33. Bateman M, Oladele R, Kolls JK. Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. Med Mycol 2020; 58: 1015-1028.
34. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infec-
tions in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America.
Erişim: https://clinicalinfo.hiv.gov/en/guidelines/adult-andadolescent-opportunistic-infection. Erişim tarihi (13 Aralık 2023) [Y1-Y18].
35. Dunbar A, Schauwvlieghe A, Algoe S, et al. Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis. Front Cell Infect Microbiol 2020; 10: 224.
36. Tasaka S. Recent Advances in the Diagnosis and Management of Pneumocystis Pneumonia. Tuberc Respir Dis 2020; 83: 132-140.
37. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17: 770-
782.
38. Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther 2010; 8: 683-701.
39. Gingerich AD, Norris KA, Mousa JJ. Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments. Pathogens 2021; 10: 236.
40. Gharamti AA, Mundo W, Chastain DB, Franco-Paredes C, Henao-Martínez AF, Shapiro L. Pneumocystis jirovecii pneumonia: a proposed novel model of corticosteroid benefit. Ther Adv
Infect Dis 2021; 8: 1-5.
41. Sharma N, Seal R, Teja DU, Pannu AK. Cystic Pneumocystis pneumonia. BMJ Case Rep 2023; 16: e255853.
42. Wang D, Hu Y, Li T, Rong HM, Tong ZH. Diagnosis of Pneumocystis jirovecii pneumonia with serum cell-free DNA in non-HIV-infected immunocompromised patients. Oncotarget 2017; 8:
71946-71953.
43. Goterris L, Mancebo Fernández MA, Aguilar-Company J, Falcó V, Ruiz-Camps I, Martín-Gómez MT. Molecular Diagnosis of Pneumocystis jirovecii Pneumonia by Use of Oral Wash Samples in
Immunocompromised Patients: Usefulness and Importance of the DNA Target. J Clin Microbiol 2019; 22; 57: e01287-19.
44. Matouri R, Aboutalebian S, Nasri E, et al. Molecular and microscopy detection of Pneumocystis jirovecii in hospitalized patients during the COVID-19 pandemic. Front Med 2023; 10: 1148320.
45. Bigot J, Vellaissamy S, Senghor Y, Hennequin C, Guitard J. Usefulness of ß-D-Glucan Assay for the First-Line Diagnosis of Pneumocystis Pneumonia and for Discriminating between Pneu-
mocystis Colonization and Pneumocystis Pneumonia. J Fungi 2022; 8: 663.
46. Hammarström H, Grankvist A, Broman I, et al. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIVinfected patients:
a retrospective case control study. BMC Infect Dis 2019; 19: 658.
47. Li X, Li Z, Ye J, Ye W. Diagnostic performance of metagenomic next-generation sequencing for Pneumocystis jirovecii pneumonia. BMC Infect Dis 2023; 23: 455.
48. Lagrou K, Chen S, Masur H, et al. Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodefi-
ciency Virus. CID 2021; 72 (Suppl. 2): S114-20.
49. Alanio A, Hauser PM, K Lagrou, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
J Antimicrob Chemother 2016 Sep; 71: 2386-2396.
50. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
J Antimicrob Chemother 2016 Sep; 71: 2397-404.
51. Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother
2016 Sep; 71: 2405-13.
52. De la Horra C, Friaza V, Morilla R, et al. Update on Dihydropteroate Synthase (DHPS) Mutations in Pneumocystis jirovecii. J Fungi 2021; 7: 856.